HHM Wealth Advisors LLC Purchases 325 Shares of AstraZeneca PLC (NASDAQ:AZN)

HHM Wealth Advisors LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 38.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,163 shares of the company’s stock after acquiring an additional 325 shares during the quarter. HHM Wealth Advisors LLC’s holdings in AstraZeneca were worth $76,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Bank of Montreal Can boosted its stake in shares of AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after acquiring an additional 1,605,758 shares during the last quarter. Franklin Resources Inc. increased its holdings in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after buying an additional 1,522,715 shares during the period. Erste Asset Management GmbH purchased a new stake in AstraZeneca during the third quarter valued at approximately $72,437,000. Manning & Napier Advisors LLC grew its position in AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock worth $245,407,000 after purchasing an additional 564,297 shares during the last quarter. Finally, Fisher Asset Management LLC increased its holdings in AstraZeneca by 5.3% in the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after buying an additional 524,175 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AZN shares. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

NASDAQ:AZN opened at $69.86 on Tuesday. The business’s 50-day moving average price is $67.08 and its 200 day moving average price is $73.85. The firm has a market cap of $216.64 billion, a P/E ratio of 33.43, a PEG ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business earned $0.87 EPS. The firm’s revenue was up 18.0% compared to the same quarter last year. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.